- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02882204
Tracking Outcomes in Psychosis (TOPSY)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES: The objective of this study is to investigate the pathophysiology of Formal Thought Disorder and variable outcomes in the early stages of schizophrenia. In particular, investigators aim to test the hypothesis that 1. Anatomical abnormalities involving the grey matter of the Anterior Insula and Medial Prefrontal Cortex in first episode schizophrenia predicts FTD that persists by 6 months of illness 2. An excess of glutamine/glutamate, or reduction in glutathione, in Medial Prefrontal Cortex at index episode will be associated with persistent FTD 3.Aberrant connectivity between Anterior Insula and Medial Prefrontal Cortex will specifically predict the severity of persistent FTD irrespective of the stage of illness; the change in this connectivity will track the variable 3-year outcome among patients with first episode of psychosis.
METHODS: This study will employ a cross-sectional design recruiting n=126 participants from the Prevention & Early Intervention Program for Psychoses (PEPP). Four groups of participants will be assessed: patients at a later stage of schizophrenia (chronic illness group) (n=42), newly referred first episode group of PEPP patients (n=84), Clinical High Risk patients (n=60) and healthy Controls (n=45). Measurements: Patients will be diagnosed using the criteria for schizophrenia according to DSM-V(34). Demographic variables such as age, gender and parental socioeconomic status will be recorded to adjust for potential confounding effects. Patients will undergo baseline assessments to assess seven features of FTD (poverty of speech, weakening of goal, perseveration, looseness, peculiar word usage, peculiar sentence usage and peculiar logic) in line with the validated procedure for administering Thought Language Index [TLI](17). First episode patients will undergo four 7T MRI scanning sessions over the course of 2.5 years (baseline, 6 months, 18 months, 30 months)lasting for 60 minutes each, as described in our previous work (15). During this time, researchers will perform MR spectroscopy (MPFC voxel (31)), T1 weighted structural scan and eyes-closed, task-free, 6 minutes resting-state functional MRI. 6 months after the onset of first episode, the clinical assessment will be repeated using TLI. Patients with persistent FTD will be identified (from previous studies, 40% of patients are expected to have persistent FTD (9)) and separated from patients who have no FTD at 6-months time point. Patients with established illness will undergo only 2 scans: baseline and 1 year later.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Lena Palaniyappan, MD, PhD
- Número de teléfono: 519.685.8054
- Correo electrónico: lena.palaniyappan.@lhsc.on.ca
Ubicaciones de estudio
-
-
Ontario
-
London, Ontario, Canadá, N6A 5B7
- Reclutamiento
- Robarts Research
-
Contacto:
- Lena Palaniyappan, MBBS, PhD
- Número de teléfono: 519-685-8054
- Correo electrónico: lena.palaniyappan@lhsc.on.ca
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Study population includes two groups of individuals:
- First Episode psychotic patients: This group will contain 84 new patients enrolled in the Prevention and early Intervention Program for Psychosis.
- Chronic Patients: This group will contain 42 patients who have been enrolled in the Prevention and Early Intervention Program for Psychosis for >3 years.
- Healthy Controls: This group will contain 42 healthy controls not being treated for a major mental illness defined using DSM-V criteria.
Descripción
Inclusion Criteria:
- 16-45 years old
- Outpatient of the Prevention and Early Intervention Program for Psychosis
Exclusion Criteria:
- Drug or alcohol dependence in past year
- History of head injury (with associated unconsciousness for any period)
- Mental retardation or suffering from medical conditions such as untreated hypertension, diabetes, hepatic/renal insufficiency, neurological illnesses
- Otherwise unable to provide informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
First Episode Patients
First episode patients new to the PEPP program.
|
|
Chronic Patients
Existing patients who have been enrolled in the PEPP program for >3 years
|
|
Healthy Controls
Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
|
|
Cliniucal High Risk patients
Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Thought Language Index Score between baseline and 6 months
Periodo de tiempo: 6 Months
|
Predicting the change in TLI score based on baseline anatomical abnormalities identified through MRI
|
6 Months
|
|
Time to remission of positive symptoms of psychosis
Periodo de tiempo: 30 months
|
The time between baseline and remission of positive symptoms based on PANSS-8
|
30 months
|
|
Time to remission of negative symptoms of psychosis
Periodo de tiempo: 30 months
|
The amount of time between baseline and remission of negative symptoms based on PANSS-8
|
30 months
|
|
Emergence of treatment resistance using operational criteria
Periodo de tiempo: 30 months
|
30 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Thought Language Index score between baseline and longitudinal follow up-dates (12 months, 18 months, 24 months and 30 months)
Periodo de tiempo: 1-2.5 years
|
Net change in TLI score as predicted by anatomical abnormalities associated with imaging at various imaging time points.
|
1-2.5 years
|
|
Change in overall symptoms over time
Periodo de tiempo: 30 months
|
Tracking changes in scores on the PANSS-8 over the 30 months of follow up for first episode patients
|
30 months
|
|
Changes in myelin content
Periodo de tiempo: 30 months (follow up period for first episode patients)
|
Longitudinal changes in myelin content as measured using quantitative t1 images
|
30 months (follow up period for first episode patients)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Publicaciones Generales
- Harrow M, Marengo JT. Schizophrenic thought disorder at followup: its persistence and prognostic significance. Schizophr Bull. 1986;12(3):373-93. doi: 10.1093/schbul/12.3.373.
- Palaniyappan L, Mahmood J, Balain V, Mougin O, Gowland PA, Liddle PF. Structural correlates of formal thought disorder in schizophrenia: An ultra-high field multivariate morphometry study. Schizophr Res. 2015 Oct;168(1-2):305-12. doi: 10.1016/j.schres.2015.07.022. Epub 2015 Jul 29.
- Liddle PF, Ngan ET, Caissie SL, Anderson CM, Bates AT, Quested DJ, White R, Weg R. Thought and Language Index: an instrument for assessing thought and language in schizophrenia. Br J Psychiatry. 2002 Oct;181:326-30. doi: 10.1192/bjp.181.4.326.
- Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW, Menon RS, Rajakumar N, Pavlosky WF, Densmore M, Schaefer B, Williamson PC. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011 Jun;198(6):448-56. doi: 10.1192/bjp.bp.110.079608.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-5®) (2013).
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 10014067
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .